{"article_title": "Acorda Therapeutics Shares Surge After Denial of Patent Challenge", "article_keywords": ["unusual", "therapeutics", "patent", "trademark", "challenge", "acorda", "shares", "surge", "denial", "trading", "board", "strategy", "review", "patents", "stock"], "article_url": "http://www.wsj.com/articles/acorda-therapeutics-shares-surge-after-denial-of-patent-challenge-1440457321", "article_text": "A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices.\n\nThe U.S. Patent and Trademark Office\u2019s review board ruled against Mr. Bass\u2019s challenge of two patents on Acorda Therapeutics Inc.\u2019s multiple sclerosis drug Ampyra. In...", "article_metadata": {"article.template": "snippet", "article.created": "2015-08-24T23:02:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "A U.S. patent review board Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices.", "creator": "@joewalkerWSJ", "image": {"alt": "Acorda Therapeutics shares surge after denial of patent challenge", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "title": "Acorda Therapeutics Shares Surge After Denial of Patent Challenge", "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB12364240996500314105804581191230864273042&headline=Acorda%20Therapeutics%20shares%20surge%20after%20denial%20of%20patent%20challenge&weburl=http://www.wsj.com/articles/SB12364240996500314105804581191230864273042"}}, "page.site.product": "WSJ", "keywords": "acorda therapeutics inc.,hedge-fund manager kyle bass,multiple sclerosis drug,multiple sclerosis treatment,Acorda Therapeutics,ACOR,U.S. Patent and Trademark Office,Appeal Board,Hayman Capital Management,Celgene,CELG,Kyle Bass,patents,financial performance,share price movement,disruptions,corporate,industrial news,intellectual property rights,industrial property rights,biotechnology,pharmaceuticals,medical equipment,supplies,health care,life sciences,biopharmaceuticals,medical,surgical instruments,apparatus,devices,therapeutic devices,equipment", "news_keywords": "acorda therapeutics inc.,hedge-fund manager kyle bass,multiple sclerosis drug,multiple sclerosis treatment,Acorda Therapeutics,ACOR,U.S. Patent and Trademark Office,Appeal Board,Hayman Capital Management,Celgene", "article.headline": "Acorda Therapeutics shares surge after denial of patent challenge", "description": "A U.S. patent review board Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB12364240996500314105804581191230864273042&headline=Acorda%20Therapeutics%20shares%20surge%20after%20denial%20of%20patent%20challenge&weburl=http://www.wsj.com/articles/SB12364240996500314105804581191230864273042", "user.type": "nonsubscriber", "article.page": "Health", "page.content.format": "responsive", "article.summary": "A U.S. patent review board Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-08-24T23:55:00.000Z", "dj.asn": "i-c645", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 2, "word_count": 379, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "A U.S. patent review board Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices.", "title": "Acorda Therapeutics Shares Surge After Denial of Patent Challenge", "url": "http://www.wsj.com/articles/acorda-therapeutics-shares-surge-after-denial-of-patent-challenge-1440457321", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Joseph Walker", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Acorda Therapeutics Shares Surge After Denial of Patent Challenge", "article.type": "Pharmalot", "article.id": "SB12364240996500314105804581191230864273042", "user.exp": "default", "article.updated": "2015-08-24T23:55:00.000Z"}, "article_summary": "The U.S. Patent and Trademark Office\u2019s review board ruled against Mr. Bass\u2019s challenge of two patents on Acorda Therapeutics Inc.\u2019s multiple sclerosis drug Ampyra.\nA U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices."}